CA2380787A1 - Source de synthase d'oxyde nitrique microencapsulee - Google Patents

Source de synthase d'oxyde nitrique microencapsulee Download PDF

Info

Publication number
CA2380787A1
CA2380787A1 CA002380787A CA2380787A CA2380787A1 CA 2380787 A1 CA2380787 A1 CA 2380787A1 CA 002380787 A CA002380787 A CA 002380787A CA 2380787 A CA2380787 A CA 2380787A CA 2380787 A1 CA2380787 A1 CA 2380787A1
Authority
CA
Canada
Prior art keywords
microcapsules
cells
nos
ecdysone
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380787A
Other languages
English (en)
Inventor
Lizhi Liu
Weiming Xu
Ian George Charles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918076.2A external-priority patent/GB9918076D0/en
Priority claimed from GB0016172A external-priority patent/GB0016172D0/en
Application filed by Individual filed Critical Individual
Publication of CA2380787A1 publication Critical patent/CA2380787A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

L'invention concerne des microcapsules pouvant être administrées à l'homme ou à l'animal, qui hébergent des cellules contenant une construction polynucléotidique. Cette dernière comporte: (a) un promoteur qui réagit à l'ecdysone ou analogue et qui est fonctionnellement lié à une séquence de codage d'une synthase d'oxyde nitrique (NOS) ou d'une variante de celle-ci; ou (b) un promoteur fonctionnellement lié à au moins une séquence de site opérateur de tétracycline et une séquence de codage dans cet ordre, ladite séquence de codage codant une synthase d'oxyde nitrique (NOS) ou une variante fonctionnelle de celle-ci. Les microcapsules peuvent être utilisées dans le traitement de conditions concernant la production anormale d'oxyde nitrique.
CA002380787A 1999-07-30 2000-07-28 Source de synthase d'oxyde nitrique microencapsulee Abandoned CA2380787A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9918076.2A GB9918076D0 (en) 1999-07-30 1999-07-30 Microencapsulated nitric oxide synthase source
GB9918076.2 1999-07-30
GB0016172A GB0016172D0 (en) 2000-06-30 2000-06-30 Microencapsulated nitric oxide synthase source
GB0016172.9 2000-06-30
PCT/GB2000/002924 WO2001009342A1 (fr) 1999-07-30 2000-07-28 Source de synthase d'oxyde nitrique microencapsulee

Publications (1)

Publication Number Publication Date
CA2380787A1 true CA2380787A1 (fr) 2001-02-08

Family

ID=26244581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380787A Abandoned CA2380787A1 (fr) 1999-07-30 2000-07-28 Source de synthase d'oxyde nitrique microencapsulee

Country Status (5)

Country Link
EP (1) EP1203084A1 (fr)
JP (1) JP2003506047A (fr)
AU (1) AU6174500A (fr)
CA (1) CA2380787A1 (fr)
WO (1) WO2001009342A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT105489B (pt) * 2011-01-18 2014-05-13 Ass For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec Dispositivo, método e sistema de fabrico de microcápsulas
US9555007B2 (en) 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
CN115487779B (zh) * 2022-06-01 2023-07-28 同济大学 一种二价铁离子/纤维素纳米晶体/海藻酸钠复合材料的制备方法及对四环素的吸附应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800829A (en) * 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
US5658565A (en) * 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6333318B1 (en) * 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto

Also Published As

Publication number Publication date
JP2003506047A (ja) 2003-02-18
WO2001009342A1 (fr) 2001-02-08
EP1203084A1 (fr) 2002-05-08
AU6174500A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
Al-Hendy et al. Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts—an alternate approach to somatic gene therapy
CN101883777B (zh) 成纤维细胞生长因子受体4表达的反义调节
AU2005302408B2 (en) Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US20050289658A1 (en) System for regulating in vivo the expression of a transgene by conditional inhibition
Serguera et al. Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells
US6103226A (en) Genetically engineered cells that produce produce L. Dopa
Mitanchez et al. Glucose-stimulated genes and prospects of gene therapy for type I diabetes
JPH10501792A (ja) カプセル化細胞の宿主への移植方法
EP0289034B1 (fr) Implantation transcaryotique
DE69927249T2 (de) Induzierendes alphavirengen- expressionssystem
WO1997034915A9 (fr) Molecule et procede d'introduction d'adn dans un noyau
Tseng et al. An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy
Fuerstenberg et al. Transcriptional repression of band 3 and CAII in v‐erbA transformed erythroblasts accounts for an important part of the leukaemic phenotype.
KR20020013486A (ko) 전사 조절부위로서 이종 유전자의 프로모터와 원래 유전자시작 코돈의 상부에 위치한 모든 5' 비해독 부위를 갖는고효율 동물세포 발현벡터
JPH0235091A (ja) 哺乳動物細胞における発現の制御
EP1534832A2 (fr) Compositions et methodes d'inhibition a specificite ou declenchement tissulaire de l'expression de genes
CA2380787A1 (fr) Source de synthase d'oxyde nitrique microencapsulee
Basic et al. Microencapsulation and transplantation of genetically engineered cells: a new approach to somatic gene therapy
Efron et al. A novel method of studying wound healing
US6106827A (en) Method of producing genetically modified astrocytes and uses thereof
US6743780B1 (en) Plasmid stabilization
AU724537B2 (en) Method for gene transfer to the central nervous system
US20030059941A1 (en) Transduced marrow stromal cells
US20030004125A1 (en) Inducible gene
CN114507695B (zh) 一种用于调控神经元活性的重组载体和方法

Legal Events

Date Code Title Description
FZDE Dead